US Patent 11174252 Heterocyclic compounds as kinase inhibitors
Patent 11174252 was granted and assigned to Nuvation Bio on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+226 characters)
Article
Patent abstract
Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+9 properties)
Infobox
Patent Inventor Names
Amit Shete0
Anil Kumar Agarwal0
Bhawana Bhatt0
Brahmam Pujala0
Jayakanth Kankanala0
Jiyun Chen0
Sanjeev Soni0
Sarvajit Chakravarty0
Son Minh Pham0
Edits on 21 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111742520
Date of Patent
November 16, 2021
0Patent Application Number
162773550
Date Filed
February 15, 2019
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 18 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11174252 Heterocyclic compounds as kinase inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11174252
Date of patent
November 16, 2021
Patent application number
16277355
Date Filed
February 15, 2019
Patent primary examiner
Find more entities like US Patent 11174252 Heterocyclic compounds as kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
